Glipox

Glipox is a prescription medication that contains the active ingredient imatinib. It is supplied in an oral dosage form, though specific strength information is not disclosed. Imatinib belongs to the tyrosine kinase inhibitor class and is used as an antineoplastic agent. The product is marketed in the European Union and requires a physician’s prescription. Glipox is intended for patients diagnosed with certain cancers and is administered under medical supervision.

Glipox (imatinib) is indicated for the treatment of specific malignancies where abnormal tyrosine kinase activity drives disease progression.

- Chronic myeloid leukemia (CML), including newly diagnosed and accelerated phases. - Gastrointestinal stromal tumor (GIST) that is unresectable, metastatic, or recurrent. - Certain rare tumors that express the BCR‑ABL fusion protein. - Off‑label use in selected cases of Philadelphia chromosome‑positive acute lymphoblastic leukemia under specialist guidance. - As part of combination therapy for selected solid tumors in clinical trials.

Glipox may cause a range of adverse effects; they are categorized by frequency and clinical significance.

Common: - Fatigue or weakness. - Nausea, vomiting or loss of appetite. - Fluid retention causing peripheral edema.

Serious: - Low blood cell counts such as neutropenia or thrombocytopenia. - Liver enzyme elevations indicating possible hepatotoxicity. - Severe skin reactions including Stevens‑Johnson syndrome.

Before initiating Glipox, clinicians should evaluate several safety considerations to minimize risk.

- Baseline complete blood count and liver function tests are recommended. - Monitor blood counts regularly during therapy for cytopenias. - Assess cardiac function in patients with pre‑existing heart disease. - Use caution in patients with renal impairment; dose adjustment may be required. - Pregnancy and breastfeeding status should be reviewed, as safety data are limited.

Glipox can interact with other medicines that affect its metabolism or increase toxicity risk.

Avoid: - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) that may reduce imatinib exposure. - Concomitant use with potent CYP3A4 inhibitors (e.g., ketoconazole) that may increase toxicity.

Use with caution: - Antacids or proton pump inhibitors that alter gastric pH may affect absorption. - Warfarin, as imatinib can affect INR. - Vaccines, especially live attenuated, due to immunosuppression risk.